生物制剂治疗主动脉上型大动脉炎可改善脑缺血症状而无需手术
该研究回顾性分析了2010—2018年单中心145例大动脉炎患者,其中8例(5.5%)因主动脉上动脉病变出现脑缺血。7例接受长期联合免疫抑制治疗、6例使用生物制剂,中位随访37个月,疾病活动度、脑缺血评分及泼尼松龙需求量显著下降,影像学未见动脉病变进展,仅1例因持续神经症状需手术。
要点
- 主动脉上型大动脉炎合并脑缺血患者早期升级至生物制剂可能减少手术需求。
- 本队列中8例(5.5%)出现脑缺血,6例使用生物制剂,仅1例需手术干预。
- 中位随访37个月,疾病活动度、脑缺血评分与泼尼松龙剂量显著下降。
核心结论
- 在主动脉上型大动脉炎合并脑缺血的患者中,早期使用生物制剂可能减少需要手术干预的人数并改善结局。
研究设计与样本
- 对2010—2018年就诊于Imperial College Healthcare的145例大动脉炎患者进行回顾性综述,识别其中因主动脉上动脉病变继发脑缺血者并分析其治疗与结局。
主要发现
- 145例中识别出8例(5.5%)脑缺血患者,7例接受长期联合免疫抑制治疗,6例使用生物制剂。
- 中位随访37个月,疾病活动度、脑缺血评分及所需泼尼松龙剂量显著下降,反应优于预期。
- 连续影像学分析显示启动最佳治疗后未见动脉病变进展,仅1例因持续神经症状需手术干预。
临床怎么用
- 对主动脉上型大动脉炎合并脑缺血者,可在联合免疫抑制基础上早期升级生物制剂,以减少对高风险血运重建手术的依赖。
局限性
- 本研究为单中心回顾性综述,脑缺血患者仅8例,样本量小,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Takayasu arteritis commonly results in severe arterial injury with stenoses, occlusions and occasionally aneurysms. Arterial disease may compromise organ blood flow and result in significant cardiovascular morbidity and premature mortality. Involvement of the supra-aortic arteries is common, and in its most severe form may compromise cerebral blood supply, resulting in signs of cerebral ischaemia including visual impairment, dysphasia, transient hemiparesis, loss of consciousness and stroke. In addition to combination immunosuppression, the management paradigm for symptomatic cerebral ischaemia includes revascularization. The invasive nature of this surgery, the risk of complications and the relatively high rate of re-stenosis is of concern to patients and their physicians alike. The aim of this study was to determine whether combined immunosuppression with early escalation to biologic therapy improved outcomes and reduced the need for high risk surgical intervention. METHODS: A retrospective review of 145 Takayasu arteritis patients attending Imperial College Healthcare between 2010-2018 was conducted to identify those with cerebral ischaemia secondary to supra-aortic disease and to analyse their treatment and outcomes. RESULTS: Eight patients (5.5%) were identified. Seven patients received long-term combined immunosuppressive therapy and six were prescribed biologics. The data revealed a higher than expected comprehensive response to therapy, with significant falls in disease activity, the cerebral ischaemia score and the prednisolone dose required, over a median follow-up of 37 months. Serial imaging analysis detected no arterial disease progression after the initiation of optimal therapy. Only one patient required surgical intervention for persistent neurological symptoms. CONCLUSION: Early use of biologic therapy in those with supra-aortic Takayasu arteritis presenting with cerebral ischaemia may reduce the numbers of patients requiring surgical intervention and improve outcomes.
引用
- Porter A, Youngstein T, Tombetti E, et al. Biologic therapy in supra-aortic Takayasu arteritis can improve symptoms of cerebral ischaemia without surgical intervention. Rheumatology (Oxford). 2020. PMID: 32348517. doi:10.1093/rheumatology/kez616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。